ALK Inhibitors – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
ALK INHIBITORS
• The “ALK Inhibitors-Pipeline Insights 2018? report covers an in-depth analysis of ALK inhibitors drug molecules currently undergoing clinical studies.
• It provides a deep understanding of potential ALK inhibitors drug molecules across all drug development phases. The report assesses the pipeline ALK inhibitors molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products) molecule type (small molecules, biologics) and route of administration (oral, IV, and others). The report provides a snapshot of discontinued and dormant drugs too.
• Also, the report includes critical insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
• The report covers company profiles key players in developing ALK inhibitors drug molecules. The company profile includes essential info on overview, financial highlights, product portfolio, business strategies, and key recent developments.
MARKET OUTLOOK
• Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that belongs to the super-family of insulin receptor (IR).
• The ALK gene in humans encodes ALK, and immunohistochemical analysis reveals that ALK expression is partially scattered in neural cells, pericytes and endothelial cells in the brain of adult human tissues. ALK mRNA is also found to be expressed in the small intestine, prostate, testis, and colon.
• ALK was initially identified as the product of a gene rearrangement in the case of anaplastic large cell lymphoma (ALCL). ALK was eventually found to be rearranged, mutated, or amplified in a series of tumors including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, diffuse large B cell lymphoma, renal cell carcinoma, colon cancer, breast carcinoma neuroblastoma, and esophageal cancer.
• The marketed ALK inhibitors currently in the market include Zykadia (ceritinib) and Alecensa (alectinib) that are indicated for the treatment of gastrointestinal cancer and non-small cell lung cancer.
• The ALK inhibitors pipeline includes more than 15 molecules, and they are expected to achieve regulatory approval shortly, few of which include – ensartinib (X-396), CEP-28122, X-376, X-390, EBI-600215. Recently in the last few years, novel potent ALK inhibitors have become available with promising results and a good toxicity profile that includes ceritinib (LDK378), brigatinib (AP26113), entrectinib (RXDX-101).
RESEARCH INSIGHTS
• The theories and practices of individualized cancer therapy have significantly influenced the approval of the first-generation ALK inhibitor, crizotinib (XalkoriTM; Pfizer), by the US FDA. Second-generation ALK inhibitors (ceritinib [Zykadia], alectinib [Alectinib], and brigatinib [Alunbrig]) were developed to increase anti-ALK activity, to overcome crizotinib-resistant mutations and to improve their business in CNS disease.
• Crizotinib has become the reference treatment for ALK+ NSCLC patients and a promising treatment for tumors. Unfortunately, many patients have developed acquired resistance in the first year of therapy and thus its efficacy is limited to CNS disease.
• Thus strategies urgently have to be developed to overcome inherent and acquired resistance of using ALK inhibitors. Nowadays, several second-generation ALK inhibitors are under various stages of clinical development that are showing activity in crizotinib-resistant disease with promising activity in CNS disease patients.
• The third-generation (such as lorlatinib) ALK inhibitors also came into existence in patients with CNS involvement.
• The goal of increasing inhibitory activity against ALK and defeating the inevitable development of drug resistance add fuel to the emergence of new ALK inhibitors.
• The procedure of resistance presents the need for new collaborations and education within the multi-disciplinary team. In the sequence of generalized progression, an understanding of the present molecular mechanism of resistance is evolved as a key to decision-making and clinical management that highlights the role of the pathologist.
• The strong clinical evidence showed that ALK is one a key driving factor of oncogenesis, which will make it a key drug target.
• A key challenge is to understand that why ALK-positive patients are not getting benefit from checkpoint inhibition and the need to develop new therapeutic strategies to tackle the immune system to identify ALK-positive cancers effectively.
THE SCOPE OF THE REPORT
• Provides comprehensive understanding of active ALK inhibitors pipeline drug candidates
• Includes a comprehensive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
• Provides a comparative analysis of key marketed products and pipeline drug candidates
• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
• Provides essential info on players involved in clinical R&D of ALK inhibitors drug candidates.
• Provides in-depth coverage of important news related to ALK inhibitors drug molecules, including significant mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.
REASONS FOR PURCHASING THIS REPORT?
• To obtain an understanding of the current ALK inhibitors pipeline landscape.
• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
• To valuably optimize R&D activities in-line with robust therapeutic drug markets.
• To devise strategic initiatives by identifying prospective partners with progressing projects.
• The “ALK Inhibitors-Pipeline Insights 2018? report covers an in-depth analysis of ALK inhibitors drug molecules currently undergoing clinical studies.
• It provides a deep understanding of potential ALK inhibitors drug molecules across all drug development phases. The report assesses the pipeline ALK inhibitors molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products) molecule type (small molecules, biologics) and route of administration (oral, IV, and others). The report provides a snapshot of discontinued and dormant drugs too.
• Also, the report includes critical insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
• The report covers company profiles key players in developing ALK inhibitors drug molecules. The company profile includes essential info on overview, financial highlights, product portfolio, business strategies, and key recent developments.
MARKET OUTLOOK
• Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that belongs to the super-family of insulin receptor (IR).
• The ALK gene in humans encodes ALK, and immunohistochemical analysis reveals that ALK expression is partially scattered in neural cells, pericytes and endothelial cells in the brain of adult human tissues. ALK mRNA is also found to be expressed in the small intestine, prostate, testis, and colon.
• ALK was initially identified as the product of a gene rearrangement in the case of anaplastic large cell lymphoma (ALCL). ALK was eventually found to be rearranged, mutated, or amplified in a series of tumors including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, diffuse large B cell lymphoma, renal cell carcinoma, colon cancer, breast carcinoma neuroblastoma, and esophageal cancer.
• The marketed ALK inhibitors currently in the market include Zykadia (ceritinib) and Alecensa (alectinib) that are indicated for the treatment of gastrointestinal cancer and non-small cell lung cancer.
• The ALK inhibitors pipeline includes more than 15 molecules, and they are expected to achieve regulatory approval shortly, few of which include – ensartinib (X-396), CEP-28122, X-376, X-390, EBI-600215. Recently in the last few years, novel potent ALK inhibitors have become available with promising results and a good toxicity profile that includes ceritinib (LDK378), brigatinib (AP26113), entrectinib (RXDX-101).
RESEARCH INSIGHTS
• The theories and practices of individualized cancer therapy have significantly influenced the approval of the first-generation ALK inhibitor, crizotinib (XalkoriTM; Pfizer), by the US FDA. Second-generation ALK inhibitors (ceritinib [Zykadia], alectinib [Alectinib], and brigatinib [Alunbrig]) were developed to increase anti-ALK activity, to overcome crizotinib-resistant mutations and to improve their business in CNS disease.
• Crizotinib has become the reference treatment for ALK+ NSCLC patients and a promising treatment for tumors. Unfortunately, many patients have developed acquired resistance in the first year of therapy and thus its efficacy is limited to CNS disease.
• Thus strategies urgently have to be developed to overcome inherent and acquired resistance of using ALK inhibitors. Nowadays, several second-generation ALK inhibitors are under various stages of clinical development that are showing activity in crizotinib-resistant disease with promising activity in CNS disease patients.
• The third-generation (such as lorlatinib) ALK inhibitors also came into existence in patients with CNS involvement.
• The goal of increasing inhibitory activity against ALK and defeating the inevitable development of drug resistance add fuel to the emergence of new ALK inhibitors.
• The procedure of resistance presents the need for new collaborations and education within the multi-disciplinary team. In the sequence of generalized progression, an understanding of the present molecular mechanism of resistance is evolved as a key to decision-making and clinical management that highlights the role of the pathologist.
• The strong clinical evidence showed that ALK is one a key driving factor of oncogenesis, which will make it a key drug target.
• A key challenge is to understand that why ALK-positive patients are not getting benefit from checkpoint inhibition and the need to develop new therapeutic strategies to tackle the immune system to identify ALK-positive cancers effectively.
THE SCOPE OF THE REPORT
• Provides comprehensive understanding of active ALK inhibitors pipeline drug candidates
• Includes a comprehensive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
• Provides a comparative analysis of key marketed products and pipeline drug candidates
• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
• Provides essential info on players involved in clinical R&D of ALK inhibitors drug candidates.
• Provides in-depth coverage of important news related to ALK inhibitors drug molecules, including significant mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.
REASONS FOR PURCHASING THIS REPORT?
• To obtain an understanding of the current ALK inhibitors pipeline landscape.
• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
• To valuably optimize R&D activities in-line with robust therapeutic drug markets.
• To devise strategic initiatives by identifying prospective partners with progressing projects.
